Rheumatoid arthritis
The current guideline is the EULAR 2025 update on synthetic and biological DMARDs. It simplifies the 2022 algorithm: after methotrexate fails, everyone gets a biologic (JAK inhibitors only after a risk assessment).
Clinical pearls
- Window of opportunity: start a DMARD at diagnosis.
- MTX + short-term steroids, review at 3 months, target by 6 months.
- Treat to target: remission (Boolean or SDAI ≤3.3 / CDAI ≤2.8) or low disease activity.
- JAK inhibitors: caution if over 65, a smoker, or with CV, cancer or VTE risk.